Pulmonary embolism

Pulmonary embolism (PE) is the third leading cardiovascular cause of death after heart attacks and stroke. PE is caused by blood clots in the pulmonary arteries. These are often caused by clots from the venous system, including thrombus from trauma, surgery or deep vein thrombosis (DVT). Treatment has traditionally been systemic use of thrombolytic drugs to dissolve the clot. But in cases there is a massive, life-threatening PE, or chronic clot burden that have remained in a vessel for an extended period of time, mechanical thrombectomy and ultrasound-assisted catheter-directed thrombolysis (USCDT) is being used as more targeted and aggressive treatments.

RSS icon
Avicenna.AI, a French artificial intelligence (AI) startup co-founded by a radiologist, has received U.S. Food and Drug Administration (FDA) clearance for two new offerings designed to automatically identify cardiovascular findings in CT scans, CINA-iPE and CINA-ASPECTS.

Pulmonary embolism common in patients hospitalized with syncope

A cross-sectional study at 11 hospitals in Italy found that 17.3 percent of patients hospitalized for syncope had pulmonary embolism.

Thumbnail

Teaming Up to Treat Pulmonary Emboli: Clotbusters Illustrates Potential of Coordinated Response Programs

At one hospital, an aggressive treatment PE treatment program has dramatically reduced mortality.

Benefits don't last when discontinuing warfarin after pulmonary embolism

If patients who experience pulmonary embolism take warfarin for two years, their risk of blood clots and major bleeding are significantly reduced. However, if they stop treatment, the benefits do not last, according to a French multicenter, randomized, double-blind study published this month in JAMA.

European Commission approves Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE

Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway. Eliquis is also approved in the EU for the prevention of venous thromboembolism (VTE) in adults who have undergone elective total hip or knee replacement surgery, and for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors.

Pradaxa gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism

Boehringer Ingelheim today announces that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE). The U.S. Food and Drug Administration (FDA) approved Pradaxa for DVT and PE patients earlier this year. DVT and PE can be very dangerous; almost one in three PE patients dies within three months and four out of 10 patients suffer a repeat blood clot within 10 years of the first.

NICE clears Xarelto for pulmonary embolism

The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended the anticoagulant rivaroxaban as a possible treatment for adults with pulmonary embolism and to prevent recurrent deep vein thrombosis or pulmonary embolism.

Additional MR Techniques Improve Detection of Pulmonary Embolism

According a study published in the March issue of the journal Radiology, radiologists now have a comparable, non-ionizing option to CT for the detection of pulmonary embolism.

Radiology: Additional MR sequences improve pulmonary embolism detection

Adding two MRI sequences to a common MR pulmonary angiogram (MRPA) significantly improves detection of pulmonary embolism and could provide an alternative to CT angiography (CTA) for diagnosis, according to a study published in the April issue of Radiology.

Displaying 33 - 40 of 41

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup